End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,040 EUR | +2.51% | +2.51% | +13.33% |
02-28 | SALUS, Ljubljana, d. d. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-09 | SALUS, Ljubljana, d. d. cancelled the acquisition of Farmadent S.R.L. | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 60.55 | 72.02 | 93.94 | 148.2 | 145.1 | 189.7 |
Enterprise Value (EV) 1 | 60.68 | 72.77 | 98.21 | 143 | 142 | 189.1 |
P/E ratio | 14.1 x | 12.2 x | 9.27 x | 11.4 x | 11.1 x | 18.4 x |
Yield | 6.17% | 6.52% | 6.11% | 4.58% | 5.04% | 3.89% |
Capitalization / Revenue | 0.24 x | 0.21 x | 0.23 x | 0.32 x | 0.29 x | 0.32 x |
EV / Revenue | 0.24 x | 0.21 x | 0.25 x | 0.31 x | 0.29 x | 0.32 x |
EV / EBITDA | 8.93 x | 6.88 x | 6.96 x | 8.06 x | 8.81 x | 11.3 x |
EV / FCF | -8.18 x | 18.2 x | -87.4 x | 10.7 x | 21.7 x | 17.4 x |
FCF Yield | -12.2% | 5.48% | -1.14% | 9.35% | 4.6% | 5.75% |
Price to Book | 1.2 x | 1.32 x | 1.56 x | 2.2 x | 1.96 x | 2.45 x |
Nbr of stocks (in thousands) | 101 | 104 | 104 | 104 | 104 | 105 |
Reference price 2 | 600.0 | 690.0 | 900.0 | 1,420 | 1,390 | 1,800 |
Announcement Date | 25/04/19 | 16/03/20 | 15/03/21 | 04/03/22 | 13/03/23 | 28/02/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 253.2 | 348 | 400.7 | 458.3 | 495.7 | 599.4 |
EBITDA 1 | 6.793 | 10.58 | 14.12 | 17.76 | 16.12 | 16.71 |
EBIT 1 | 4.747 | 7.825 | 11.65 | 14.99 | 13.24 | 13.26 |
Operating Margin | 1.88% | 2.25% | 2.91% | 3.27% | 2.67% | 2.21% |
Earnings before Tax (EBT) 1 | 5.348 | 7.474 | 12.6 | 16.37 | 16.41 | 13.09 |
Net income 1 | 4.291 | 5.903 | 10.13 | 13.01 | 13.1 | 10.27 |
Net margin | 1.69% | 1.7% | 2.53% | 2.84% | 2.64% | 1.71% |
EPS 2 | 42.54 | 56.55 | 97.06 | 124.6 | 125.5 | 97.86 |
Free Cash Flow 1 | -7.418 | 3.988 | -1.123 | 13.37 | 6.538 | 10.86 |
FCF margin | -2.93% | 1.15% | -0.28% | 2.92% | 1.32% | 1.81% |
FCF Conversion (EBITDA) | - | 37.69% | - | 75.31% | 40.56% | 65% |
FCF Conversion (Net income) | - | 67.56% | - | 102.81% | 49.93% | 105.78% |
Dividend per Share 2 | 37.00 | 45.00 | 55.00 | 65.00 | 70.00 | 70.00 |
Announcement Date | 25/04/19 | 16/03/20 | 15/03/21 | 04/03/22 | 13/03/23 | 28/02/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.13 | 0.76 | 4.27 | - | - | - |
Net Cash position 1 | - | - | - | 5.17 | 3.06 | 0.59 |
Leverage (Debt/EBITDA) | 0.0197 x | 0.0714 x | 0.3026 x | - | - | - |
Free Cash Flow 1 | -7.42 | 3.99 | -1.12 | 13.4 | 6.54 | 10.9 |
ROE (net income / shareholders' equity) | 8.56% | 11.2% | 17.7% | 20.4% | 18.6% | 13.6% |
ROA (Net income/ Total Assets) | 2.67% | 3.71% | 5.15% | 5.94% | 4.82% | 4.25% |
Assets 1 | 160.5 | 158.9 | 196.6 | 218.9 | 271.9 | 242 |
Book Value Per Share 2 | 499.0 | 523.0 | 575.0 | 645.0 | 708.0 | 736.0 |
Cash Flow per Share 2 | 131.0 | 137.0 | 84.50 | 169.0 | 183.0 | 215.0 |
Capex 1 | 0.39 | 1.21 | 3.25 | 4.05 | 2.25 | 5.72 |
Capex / Sales | 0.15% | 0.35% | 0.81% | 0.88% | 0.45% | 0.95% |
Announcement Date | 25/04/19 | 16/03/20 | 15/03/21 | 04/03/22 | 13/03/23 | 28/02/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+13.33% | 232M | |
-12.76% | 8.54B | |
+33.93% | 1.35B | |
+2.22% | 274M | |
-5.50% | 88.89M | |
-46.03% | 83.22M | |
+19.24% | 59.31M |
- Stock Market
- Equities
- SALR Stock
- Financials SALUS, Ljubljana, d. d.